NHS sues Reckitt for £89m over Gaviscon supply
Your support helps us to tell the story
Our mission is to deliver unbiased, fact-based reporting that holds power to account and exposes the truth.
Whether $5 or $50, every contribution counts.
Support us to deliver journalism without an agenda.
Louise Thomas
Editor
The Health Secretary Andrew Lansley and the National Health Service are suing the consumer-goods group Reckitt Benckiser for £89m over the supply of Gaviscon, the company's heartburn medicine.
The case comes after Reckitt was fined £10.2m by the Office of Fair Trading (OFT) in October for admitting abuse of its dominant position in the supply of Gaviscon. The company admitted infringing British and European competition law by withdrawing its profitable Gaviscon Original Liquid from the National Health Service's prescription list after its patent expired in 2005. The move meant that prescriptions would be issued for Gaviscon Advance Liquid, which was protected by patent.
"Vigorous competition between firms supplying the public sector is vital to ensure taxpayers get the best value for money," the OFT's chief executive, John Fingleton, said when the fine was announced last year.
When contacted, Reckitt declined to comment on the Health Secretary's case.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments